Małgorzata P.
- Country
- Poland
- Department
- Klinika Immunologii
Research Overview
- Evaluation of Long-term Safety and Tolerability of Human Normal Immunoglobulin and Hyaluronidase (Human Recombinant) in Primary Immunodeficiency Diseases
- Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
Data & Insights
Has run more than one trial at 15 of 26 partner sites.
Specializations
Immunology Research
This investigator specializes in studying Primary Immunodeficiency Diseases (PIDD), focusing on innovative therapeutic approaches for patients with compromised immune systems.
- Immune System Disorders
- Long-term Treatment Solutions
- Immunoglobulin Therapy
The research encompasses evaluating novel therapeutic options for managing primary immunodeficiency conditions.
Clinical Pharmacology
The investigator conducts research in pharmacokinetics of immunological treatments, with particular attention to subcutaneous administration methods.
- Drug Absorption Studies
- Medication Tolerability
- Therapeutic Comparability
Their work includes assessment of steady-state pharmacokinetics in immunodeficiency treatments.
Treatment Safety
The investigator focuses on safety and tolerability evaluations of immunological therapies, particularly in long-term treatment scenarios.
- Long-term Safety Monitoring
- Treatment Tolerability
- Patient Response Assessment
Their research emphasizes comprehensive safety profiles of immunological interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.